InterCure Ltd. (INCR) Fair Value 2026

INCR · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, InterCure Ltd. (INCR) trades at $5.78. QOC: 6.1/10. Value Trap Risk: 25/100 (LOW). 1/13 models active.

Key Facts

Ticker
INCR
Price
$5.78
Quality Score
6.1/10
Value Trap Risk
25/100
Models Active
1/13
Last Updated
Strength: FTNN Topology suggests +117.9% upside with 4% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give INCR?

1 Intrinsic Value Models vs. Current Price ($5.78)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $12.59 +117.9%

All Models Active

All 1 models are displayed above.

What Is InterCure Ltd. (INCR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for InterCure Ltd.. Trading at $5.78 against an estimated intrinsic value of $12.59, 1 of 1 active models flag meaningful upside of +117.9% at the median.

What Do the Models Say About INCR?

1 of 13 models are currently active for INCR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does INCR Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, INCR ranks #52 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

InterCure Ltd.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is INCR a Value Trap?

CirclFi's Value Trap algorithm assigns INCR a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for InterCure Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, InterCure Ltd. earns a quality score of 6.1/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INCR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across INCR's 1 active models, average confidence is 4%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy InterCure Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AYTUAytu BioPharma, Inc.QOC 6.1SBFMSunshine Biopharma, Inc.QOC 6.1SCYXSCYNEXIS, Inc.QOC 6.1INISRadnostix, Inc.QOC 6.1EOLSEvolus, Inc.QOC 6.2AAWHAscend Wellness Holdings, Inc.QOC 6.1APUSApimeds Pharmaceuticals US, Inc.QOC 5.0KMDAKamada Ltd.QOC 2.6TRLVTrulieve Cannabis Corp.QOC 7.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: AYTU · SBFM · SCYX · INIS · EOLS · AAWH · APUS · KMDA · TRLV · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to INCR?

6 companies across all industries closest to INCR’s Quality of Company score of 6.1/10.

OMOutset Medical, Inc.QOC 6.1TXOTXO Partners, L.P.QOC 6.1NSPRInspireMD, Inc.QOC 6.1ECHOEchoStar CorporationQOC 6.1CCThe Chemours CompanyQOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OM · TXO · NSPR · ECHO · CC · NVDA

Where Does INCR Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

INCR is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About InterCure Ltd.’s Valuation?

What is InterCure Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for InterCure Ltd. (INCR). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INCR overvalued or undervalued right now?

At $5.78, 1 of 1 active models suggest INCR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits InterCure Ltd.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.1 mean for INCR?

InterCure Ltd.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on INCR?

CirclFi analyzes INCR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is INCR a value trap in 2026?

InterCure Ltd.'s Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns InterCure Ltd. (INCR) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/INCR/ · Methodology
Primary sources for this INCR valuation
  • Financial statements: InterCure Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001857030) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INCR as of ; valuations recomputed .